ARTICLE | Clinical News

Avycaz regulatory update

July 11, 2016 7:00 AM UTC

The European Commission approved Zavicefta ceftazidime/avibactam from AstraZeneca to treat adults with complicated intra-abdominal infections (cIAI); complicated urinary tract infections (cUTI), including pyelonephritis; and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP). The product is also approved to treat infections due to aerobic Gram-negative bacterial infections in patients with limited treatment options. Zavicefta is a fixed-dose combination of ceftazidime, a third-generation cephalosporin, and avibactam, a broad-spectrum beta lactamase (LACTB) inhibitor. ...